KoichiTakahashiMD

Oncology • Houston, TX

Hematologic Oncology

Physician

Join to view full profile

Dr. Takahashi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Takahashi's full profile

Already have an account?

Office
1515 Holcombe Blvd

Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2008 - 2011
OtherClass of 2006

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2014 - 2025
OK State Medical License 2020 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition.
Xiangguo Shi, Minhua Li, Zian Liu, Jonathan Tiessen, Yuan Li
Nature Communications. 2025-03-18
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.
Warren Fiskus, Christopher P Mill, Jessica Piel, Mike Collins, Murphy Hentemann
Blood Cancer Journal. 2025-03-15
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi
Leukemia. 2025-02-25

Journal Articles

Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes
Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes
Koichi Takahashi, Nitin Jain, Courtney D. DiNardo, Steven Kornblau, Carlos Bueso-Ramos, Marina Konopleva, Hagop Kantarjian, Nature

Abstracts/Posters

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA ...
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Expression Profiling of mRNA By Next Generation Sequencing and the Development of Algorithm for Predicting Response in Acute Myeloid Leukemia
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly D...
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)
Koichi Takahashi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Diverse Landscape of TET2 Variants in MDS and AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17pOctober 2017
Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017

Press Mentions

Do Clonal Hematopoiesis and Mosaic Chromosomal Alterations Increase Solid Tumor Risk?September 6th, 2024
NEI Scientists Publish Recipe for Making Blood Vessel Cells from Patient Stem CellsMay 15th, 2023
MD Anderson Research Highlights for June 16, 2021June 16th, 2021
Join now to see all